Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab exposure-response maintenance dosing study in ulcerative colitis
2019-003987-37Phase 4Completed
- Sponsor
- University Medical Centre Ljubljana
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of golimumab in autoimmune colitis (2 arms), sponsored by University Medical Centre Ljubljana. Primary endpoint: Mucosal healing at week 14 and week 50. Started Nov 2019; status: completed.
02
Drugs
golimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2019-003987-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003987-37.